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The acceptance of the concept of hormesis, a
speciﬁc type of nonmonotonic dose response,
has accelerated in recent years (Academie
Nationale de Medecine 2005; Cendergreen
et al. 2005; Kaiser 2003; Puatanachokchai
et al. 2005; Randic and Estrada 2005; Renner
2003). Nonetheless, it has not been without its
detractors. One article critical of the concept
was published last year in Environmental
Health Perspectives (Thayer et al. 2005). It pro-
vided a summary of the major points of con-
tention and thus a convenient vehicle for us to
use in responding to opposing perspectives. 
Although Thayer et al. (2005) tacitly
acknowledged the existence of the phenome-
non, they argued that no consideration should
be given to hormesis in assessments of chemi-
cal risks for regulatory purposes. We disagree
with their conclusion, but believe some of
their points have merit—with important clari-
fications. We also believe that the proper
understanding and utilization of hormesis will
do a much better job of both protecting and
promoting public health than the policy-based
defaults that are currently in use.
Contrary to the assertion of Thayer et al.
(2005) that hormesis is rare, it is a ubiqui-
tous natural phenomenon (Calabrese and
Blain 2005). Although given many names,
hormesis has been observed in the fields of
medicine (Brandes 2005; Celik et al. 2005),
molecular biology (Randic and Estrada
2005), pharmacology (Chiueh et al. 2005),
nutrition (Lindsay 2005), aging and geriatrics
(Lamming et al. 2004; Rattan 2004a, 2004b,
2004c, 2005; Sinclair et al. 2005), agriculture
(Brandt et al. 2004; Shama and Alderson
2005), microbiology (Brugmann and Firmani
2005), immunology (Dietert 2005; Liu 2003),
toxicology (Stebbing 2000), exercise physiol-
ogy (Radak et al. 2005), and carcinogenesis
(Fukushima et al. 2005)—literally, across the
biological spectrum. It has also been observed
in relation to disparate outcomes from the
isolated single cellular process to the more
holistic (e.g., growth, longevity, disease,
death) that likely result from a complex inter-
play of multiple factors and mechanisms
(Calabrese 2005d). 
In some ﬁelds, such as pharmacology and
nutrition, these findings have been used
directly or indirectly to improve human health.
In others, they have been dismissed as artifacts
and ignored (Calabrese 2005b). For example,
certain micronutrients and vitamins can be
toxic at high levels, even though low levels are
essential to good health (Axelrod et al. 2004);
even lower levels lead to deﬁciency conditions
that are still problems of major public health
significance in some parts of the world.
Unfortunately, it is less well known that the
phenomenon has also been documented for a
host of other chemicals, including inorganic
preservatives, antineoplastic drugs, pesticides,
and various industrial chemicals (both individ-
ual agents and mixtures) (Calabrese 2005d). 
Mechanistic research conducted on some
of these agents explains the underlying biologi-
cal actions related to the respective agents at
both low and high exposures (Calabrese
2005a, 2005c; Calabrese and Baldwin 2001a;
Levchenko et al. 2004; Szabadi 1977). The
same cannot be said about many of the policy-
based defaults that are routinely used in the
current risk assessment process employed for
the development of occupational and environ-
mental health policy. Especially with regard to
low-level exposures, both the hypothetical
shape of the curves associated with these
defaults and their presumptive underlying
mechanisms are based on assumptions that are
largely untested or untestable.
Dose–Response Curve
The hormetic curve (Figure 1) can be most
easily understood in terms of low-dose stimu-
lation and high-dose inhibition. Depending
on the outcome of interest, this interplay
results in either a J-shaped or inverted
J-shaped dose response (sometimes called
“U-shaped” or “inverted U-shaped,” or
“biphasic” or “β-curve”). The point at which
the hormetic curve crosses the reference level
of response (i.e., the threshold) is the zero
equivalent point (ZEP). 
Thayer et al. (2005) believe the term
hormesis would be “better described by the
more general term ‘nonmonotonic’ dose
responses.” This suggestion does not offer any
advantages and, in fact, is simply too general.
Hormesis is a speciﬁc type of nonmonotonic
dose response, one with characteristic quanti-
tative features (Figure 2) relating to the mag-
nitude of the response, relationship of the
point of maximum stimulation to the ZEP,
the width of the stimulatory response, and
temporal features (Calabrese and Baldwin
2001b). The term “nonmonotonic” is less
precise and would simply lump unrelated phe-
nomena together. Hormesis is a much more
focused term and therefore preferable. 
Although we agree with Thayer et al.
(2005) that “there is a need to address non-
monotonic dose–response relationships in the
risk assessment process,” our particular interest
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Commentaryis in that subset classiﬁed as hormesis because of
its ubiquity and, therefore, its potential impor-
tance to public health. In fact, extensive review
of the literature has demonstrated that below-
NOEL (no observed effect level) responses are
overwhelmingly more consistent with hormesis
than with its rival models, including linear no-
threshold (LNT) dose response (Calabrese and
Baldwin 2001b, 2003).
Beneﬁcial versus Harmful
Thayer et al. (2005) argued that stimulatory
responses are not always beneficial and that
some may be harmful. We agree. In fact, either
inhibitory or stimulatory effects may be harm-
ful or beneﬁcial, a point that we have made on
numerous occasions; one example was pre-
sented by Calabrese and Baldwin (2002a):
“even though hormesis is considered an adap-
tive response, the issue of beneficial/harmful
effects should not be part of the deﬁnition of
hormesis, but reserved to a subsequent evalua-
tion of the biological and ecological context of
the response.” In the text, numerous examples
were offered. For instance, in clinical medicine,
whether a particular treatment is beneﬁcial or
not differs when viewed from the perspective
of the patient or of an attacking organism. A
dose that is sufﬁcient to inhibit the organism
likely will cure the patient; however, the
patient may die as a result of a dose that is too
low, because such a dose may stimulate the
invading organism to the extent that it over-
whelms the body’s natural defenses.
Even in situations in which deleterious
impacts on humans might occur, either in the
general population or in sensitive subgroups, it
is important to recognize that a) if hormesis
continues to be ignored by tradition or policy,
those effects likely will be overlooked; b)a
problem overlooked is a problem that can
never be properly addressed; and c) whether
there really is or is not a problem, especially
one that potentially could occur indirectly, can
be documented only by means of empirical
data (data collected via observation and experi-
ment on health effects and their underlying
mechanisms).
Nonetheless, it is also important to recog-
nize that striving to reduce some exposures ever
lower, simply because it is possible, may not
only be unnecessary for the protection of pub-
lic health, but it may be counterproductive. In
a state of ignorance, “erring on the side of
caution” may not be cautionary; it may simply
be an error—one that carries with it a host of
social penalties and/or lost opportunities. This
presumptive “precautionary” approach
arguably had utility in the past, as pointed out
by Johnson (2004) in a commentary on the
U.S. Environmental Protection Agency (EPA)
report An Examination of EPA Risk Assessment
Principles and Practices (Risk Assessment Task
Force 2004), but it is a philosophy that
became prominent during the middle of the
last century, when many of the technologies
that are currently available simply did not
exist. The time has come to move on, to begin
making risk-based decisions founded more on
actual biological data rather than on conve-
nient statistical assumptions (Kathren 1996).
Exposure Limits
As Thayer et al. (2005) noted, an environ-
mental policy that mandates an optimal point
level of exposure makes no sense, if for no
other reason than it would be technically
impossible to maintain. On the other hand,
given a situation where the nadir of the
J-shaped curve equated to beneﬁt, neither does
an exposure limit based on the LNT model
because such a limit would have the net effect
of diminishing or eliminating a beneﬁt. With
hormesis, any exposure limit below the ZEP
would protect the general public against the
risk of disease in excess of background—
including the hypothetical 1 in a million
inherent to the LNT approach—but an expo-
sure limit in the range of the maximum stimu-
lation could promote appreciable benefits in
public health. Note the differentiation
between “protect” and “promote.” The former
is basically an attempt to maintain the fre-
quency of disease near background; the latter
relates to reducing the frequency of disease
below background (i.e., improving the health
of the general public). Any exposure limit
established in a fairly broad range around the
nadir of the hormetic curve would accomplish
that goal to a greater or lesser extent. It logi-
cally follows that any exposure limit apprecia-
bly below the nadir could equate to a lost
opportunity.
All Induced Effects
Thayer et al. (2005) called for health deci-
sions to be based on “all induced effects.” We
agree, at least with all effects that likely result
from levels of exposure that actually occur in
the environment. The reliance on a sentinel
outcome in the formulation of health policy,
irrespective of whether the outcome is beneﬁ-
cial or detrimental, makes no sense, especially
in situations where the agent clearly is associ-
ated with multiple outcomes.
Ethanol is a case in point. As Lin et al.
(2005) reported, ingestion of alcohol is associ-
ated with nonlinear (hormetic) dose–response
curves for death from all causes, death from
cancer (presumptively all types), and death
from cardiovascular disease among Japanese
men. For all three disease categories, the mod-
erate intake of 0.1–22.9 g/day alcohol (equiv-
alent to one to two drinks per day) was
associated with statistically significant
decreases in the order of 20% relative to the
reference (nondrinkers, relative risk = 1) and
the highest level of consumption (≥ 69 g/day)
was associated with statistically signiﬁcant ele-
vations of approximately 40%. Favorable
mortality patterns, albeit not quite as dra-
matic, were also noted for Japanese women.
Among men, the decrease in the risk for all-
cause mortality was greater in never-smokers
than in ever-smokers. However, Lin et al.
(2005) also reported elevated risks for death
from injuries and external causes at all levels
of consumption (albeit only the highest dose
was statistically signiﬁcant). 
None of the ﬁndings are particularly sur-
prising, and one certainly should not drink and
drive. However, while health care providers
caution against its abuse, they are increasingly
advising their patients of the protective advan-
tages of the moderate, routine consumption of
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Figure 1. Schematic forms of the hormetic dose response. (A) The most common form of the hormetic
dose–response curve showing low-dose stimulatory and high-dose inhibitory responses (β- or inverted
U-shaped curve). (B) The hormetic dose–response curve depicting low-dose reduction and high-dose
enhancement of adverse effects (J- or U-shaped curve).
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Figure 2. Dose–response curve showing the quan-
titative features of hormesis. NOAEL, no observed
adverse effect level.
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(averages 10- to 20-fold)ethanol. They are doing this in spite of the fact
that the mechanisms related to harm are much
better understood than the mechanisms of
benefit, especially for such a broad category
such as death from all causes. In essence, the
clinicians are making their decisions based on
a simple risk–benefit calculation. In their
study, Lin et al. (2005) reported approxi-
mately 175 fewer deaths from all causes and
7 excess deaths from injuries and external
causes, a beneﬁcial ratio of 25:1 for the group
who consumed moderate daily amounts of
alcoholic beverages. 
Mechanisms of Action
Thayer et al. (2005) contended that little is
known about the mechanisms underlying
hormesis. Further, they argued that, in the
absence of comprehensive mechanistic foun-
dations, hormetic-like dose–response relation-
ships are meaningless. The first assertion is
incorrect, and the second, shortsighted.
It is a myth that little is known about
hormetic mechanisms. In fact, the case is just
the opposite. As early as 2001, a series of arti-
cles was published on a range of endogenous
agonists [prostaglandins (Calabrese 2001i),
nitric oxide (Calabrese 2001g), estrogens and
related compounds (Calabrese 2001e), andro-
gens (Calabrese 2001c), adrenergic agonists
(Calabrese 2001b), adenosine (Calabrese
2001a), 5-hydroxytryptamine (Calabrese
2001f), dopamine (Calabrese 2001d), and
opiates (Calabrese 2001h)] that display
hormetic biphasic dose responses. These arti-
cles documented that the mechanisms of
biphasic dose responses were clearly estab-
lished to the level of receptor and, in a number
of cases, to further levels of molecular detail.
Later assessments have identified dozens of
hormetic mechanisms for immune responses
(Calabrese 2005c) and for responses in tumor
cell lines (Calabrese 2005a). At that time,
more than two dozen receptor systems
demonstrated hormetic dose responses. In
general, the receptor systems display such
biphasic dose responses when a single agonist
has differential affinity for two opposing
receptor subtypes, a concept that was first
described in detail by Szabadi (1977). These
molecular mechanism–oriented concepts and
examples have been both reaffirmed and
extended in recent work by Levchenko et al.
(2004), who dealt with regulatory modules
that generate biphasic dose–response relation-
ships. As more research is conducted, it is likely
that even more mechanisms will be discovered
that operate at the level of the molecule, cell,
tissue, or total organism.
As previously implied (Calabrese 2005a,
2005c; Thayer et al. 2005) additional research
is needed to expand our understanding of
hormesis; however, it is shortsighted to assume
that comprehensive mechanistic knowledge is
necessary before an effect has been (or can be)
considered in health policy. The history of
medicine and public health is replete with
examples of new insights supplanting previ-
ously “well-established” concepts of disease and
how they should be addressed; for example,
asbestos, vaccinations, penicillin, and yellow
fever. The more numerous, consistent, and
coherent the ﬁndings of beneﬁt or harm, the
more readily they were accepted and acted
upon even in the absence of comprehensive
mechanistic explanations. To argue that
hormetic mechanisms require a higher level of
understanding is simply an example of a dou-
ble standard designed to accomplish little more
than maintain the status quo.
Science is an iterative process of theory,
test, conﬁrmation, and reﬁnement to ﬁt new
data and ideas. If a concept cannot be repli-
cated or sufﬁcient explanatory data developed,
it will be rejected, as was the theory of cold
fusion. Alternatively, if new observations of
beneﬁt or harm can be replicated, the public is
best served by acting upon them.
By way of example, until the latter part of
the 20th century, upper gastrointestinal inﬂam-
mation and ulcers were thought to be caused by
excessive stomach acids. Interventions, some
quite invasive and dangerous, were designed
to block the production or actions of gastric
juices. In the 1980s, two Australian investiga-
tors reported that, in most cases, these prob-
lems had an infectious etiology (Gupta 2005).
Initially, the medical community had great
difficulty accepting these findings, in part
because they rendered so much previous work
and opinion obsolete. It is now acknowledged
that an infectious agent, Helicobacter pylori, is
the major causative agent for approximately
90% of gastric ulcers and 75% of duodenal
ulcers (and quite possibly certain gastric
malignancies). Although the ultimate mecha-
nisms by which these occur are not known,
many of the problems currently are treated
successfully with antibiotics (Gupta 2005). 
There is one final problem with relying
too heavily on mechanistic research before
acting on evidence of benefit or harm. As
noted in a previously published article
(Calabrese 2005a), 
Problematic in the general area of research is that
investigators who report findings on in vitro
tumor cell proliferation do not typically cite
responses in other systems such as the immune
that could affect tumor responses, thereby rarely
approaching an integrative assessment of the
whole organism.
This suggests that such in vitro work—in isola-
tion—cannot be used to make the risk–beneﬁt
calculations like those that we described above
for alcohol. Mechanistic research, while cer-
tainly valuable, plays a much more important
role in the development of strategies for pre-
vention or intervention.
High Risk Groups 
In the recent government report An Exami-
nation of EPA Risk Assessment Principles and
Practices, the Risk Assessment Task Force
(2004) pointed out that it is not agency pol-
icy to protect the most sensitive in the general
population, just the more sensitive. With
proper knowledge, we think it may be possi-
ble to protect both subgroups against excess
risk and still promote decreased risk among
those in the general population with “normal”
sensitivity.
Responding to concerns expressed by Lave
(2001), Calabrese and Baldwin (2002b)
pointed out that previous work had never
addressed this critical area in the risk assess-
ment process. They used the hormesis data-
base to explore the responses of potential
high-risk individuals and highly sensitive
species to toxic substances. This analysis indi-
cated that those at increased risk typically dis-
played the hormetic response; it just shifted to
the left on the dose–response spectrum. In set-
ting exposure limits for a population that
included such a subset of individuals, any
limit set below the ZEP for the sensitive indi-
viduals would protect both sensitive and nor-
mal individuals against excess disease over
background. That limit likely also could pro-
vide some additional benefits to the normal
individuals (i.e., decrease the risk to that group
and thus promote improved public health).
Calabrese and Baldwin (2002b) also found
that, in about 20% of the cases, a hormetic
response was not seen and may have been a
factor in the observed increased risk. Protecting
this group is a challenge, no matter what the
underlying biological model. Calabrese and
Baldwin (2002b) concluded that there is no
conceptual or technical conflict unique to
hormesis and high-risk groups. This concept is
simply another component to an overall
sophisticated analysis of a population-based
dose response.
We fully agree that an agency could make
the decision to lower the exposure limit below
the range that optimized health for the general
public, for example, to protect the unborn or
some other segment of the population that had
been shown to be more sensitive to the puta-
tive agent. In fact, this decision might even be
made to protect a susceptible plant or animal
species; but all of these decisions, in the vernac-
ular of the U.S. EPA (Risk Assessment Task
Force 2004), would have to be “transparent.”
In other words, it would have to be acknowl-
edged that the general public likely could suffer
an increased risk to a preventable burden of
disease as a result of such a decision.
Multiple Chemical Exposures
Thayer et al. (2005) emphasized the need to
consider all chemical exposures in any risk
assessment process. As is the case of high-risk
The importance of hormesis to public health
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for hormesis than it is for any other dose–
response model. Mixture data are generally
limited, but there are sufﬁcient data on mix-
tures to indicate that hormetic effects would
routinely occur. Hormetic effects have been
reported for complex mixtures such as well-
characterized wastewater efﬂuent (Walsh et al.
1980) and petroleum mixtures (Laughlin et al.
1981). They have also been reported for more
simplified limited chemical mixtures (Flood
et al. 1985; Gennings et al. 2002).
FDA Regulation of Hormesis
Thayer et al. (2005) maintained that any bene-
ficial effects (but apparently not concurrent
detrimental effects) related to environmental
exposures need to be under the regulatory con-
trol of the Food and Drug Administration
(FDA). In part, they suggest that is because the
proponents of hormesis want “increased envi-
ronmental exposures to toxic and carcinogenic
agents.” That is a misrepresentation of our
position. What we are advocating, with the few
exceptions noted above, is that environmental
exposures only need to be lowered to the range
that maximizes public health, because driving
them much lower would place the public at
unnecessary risk to preventable disease or
death. Therefore, a regulation that mandates
limits appreciably below the nadir of the
hormetic curve would be bad public health
policy and should require justification, with
supporting data, from the agency proposing
the policy. The FDA would not be involved
with this process.
Radiation Hormesis
Thayer et al. (2005) provided a quotation from
the 2005 Biological Effects of Ionizing
Radiation (BEIR) VII report [National
Research Council (NRC) 2005] which they
implied supported their contention that
hormesis should be ignored: 
The assumption that any stimulatory hormetic
effects from low doses of ionizing radiation will
have a significant health benefit to humans that
exceeds potential detrimental effects from the radia-
tion exposure is unwarranted.
For a number of reasons, that reference was
selective and misleading. First, the quotation
was incomplete. The sentence did not end
with the word “unwarranted”; it actually
ended with “unwarranted at this time.”
Second, Thayer et al. (2005) did not mention
that among the 12 research needs recom-
mended by the BEIR VII committee, two
involved hormesis (NRC 2005). Third,
Thayer et al. did not reference the report from
the Academie Nationale de Medecine (2005). 
Both the BEIR committee (NRC 2005)
and the French committee (Academie
Nationale de Medecine 2005) issued their
reports concerning the health effects of ioniz-
ing radiation at approximately the same time;
therefore, both presumptively had access to
the same literature. They both recommended
research on hormesis, but the Academie
Nationale de Medecine (2005) went further
in that they challenged the validity of the
LNT model and stated that “the importance
of hormesis should not be overlooked.”
Conclusions
Hormetic dose–response curves have been
observed for a large number of individual
agents and various mixtures, across the biologi-
cal spectrum, and for responses ranging from
the cellular level to broad categories of disease
(Calabrese and Baldwin 2001c; Calabrese and
Blain 2005). They are too numerous to be
dismissed as artifacts and too important to be
ignored. 
Much in this field has changed over the
last few years. The topic has been included in
leading toxicologic and risk assessment texts,
taught at graduate level courses in toxicology,
and discussed at major professional meetings.
Furthermore, a growing number of inter-
national governmental advisory bodies have
begun to give detailed consideration to the
concept and its risk assessment implications,
and how these may be incorporated into the
regulatory process.
A great strength of the hormetic model
not addressed by Thayer et al. (2005) is that it
has the capacity to be tested and thereby vali-
dated or rejected with experimental data in the
observable zone. This is in contrast to the lin-
ear-at-low-dose model that U.S. government
agencies currently use to estimate cancer risk. 
The hormetic model also provides decision
makers in regulatory agencies with a much
broader array of options in the risk assessment
process; with the hormetic model, they can
consider potential beneﬁts, as well as risks, to
health among the general public and speciﬁc
subgroups. Therefore, it will allow decision
makers to consider not only how to protect
health but, more importantly, how to optimize
it. Admittedly, these choices, while attractive,
will also be challenging, in part because they
may be more complex and, in part, because
they may tend to bring various subgroups in
the population together to debate one group’s
health beneﬁt against another group’s health
risk. This will make the stakeholder concept
much more dynamic and involve a broader
array of subgroups in the population. 
The time has come to move away from the
LNT model, certainly move away from it as
the default. Acceptance of the reality of
hormesis by various government agencies in
the United States will likely accelerate the
acquisition of knowledge about this phenome-
non. More resources will become available to
conduct experiments speciﬁcally designed with
hormesis in mind. More reasoned discussions
will take place among risk assessors and risk
managers. We believe that all of these will set
the stage for actions that, directly and indi-
rectly, will result in substantial improvements
in the health of both the general public and
the environment.
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